Zacks: Analysts Expect MAXIMUS, Inc. (NYSE:MMS) Will Announce Quarterly Sales of $760.56 Million

Analysts forecast that MAXIMUS, Inc. (NYSE:MMS) will report $760.56 million in sales for the current quarter, according to Zacks. Four analysts have made estimates for MAXIMUS’s earnings. The highest sales estimate is $772.65 million and the lowest is $752.31 million. MAXIMUS reported sales of $558.45 million during the same quarter last year, which indicates a positive year over year growth rate of 36.2%. The business is scheduled to issue its next quarterly earnings results on Tuesday, November 19th.

On average, analysts expect that MAXIMUS will report full year sales of $2.90 billion for the current year, with estimates ranging from $2.88 billion to $2.92 billion. For the next year, analysts expect that the business will post sales of $3.18 billion, with estimates ranging from $3.13 billion to $3.22 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that follow MAXIMUS.

MAXIMUS (NYSE:MMS) last released its quarterly earnings data on Thursday, August 8th. The health services provider reported $0.97 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.93 by $0.04. MAXIMUS had a net margin of 8.44% and a return on equity of 20.72%. The firm had revenue of $730.70 million during the quarter, compared to analysts’ expectations of $754.81 million. During the same period last year, the business earned $0.91 earnings per share. MAXIMUS’s revenue was up 22.2% compared to the same quarter last year.

Several equities research analysts recently issued reports on the stock. Wells Fargo & Co restated a “market perform” rating and set a $83.00 price objective on shares of MAXIMUS in a research report on Friday, August 9th. Zacks Investment Research upgraded shares of MAXIMUS from a “hold” rating to a “buy” rating and set a $75.00 price target for the company in a research report on Monday, May 27th. ValuEngine cut shares of MAXIMUS from a “buy” rating to a “hold” rating in a research report on Friday, June 28th. Finally, Canaccord Genuity lifted their price target on shares of MAXIMUS from $72.00 to $77.00 and gave the company a “hold” rating in a research report on Tuesday, August 13th.

In related news, Vice Chairman Richard A. Montoni sold 11,000 shares of MAXIMUS stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $80.40, for a total value of $884,400.00. Following the completion of the transaction, the insider now owns 337,874 shares in the company, valued at $27,165,069.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Vice Chairman Richard A. Montoni sold 12,000 shares of MAXIMUS stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $78.04, for a total transaction of $936,480.00. Following the completion of the transaction, the insider now owns 337,874 shares of the company’s stock, valued at approximately $26,367,686.96. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 24,000 shares of company stock valued at $1,893,780. Company insiders own 2.20% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. Strs Ohio grew its holdings in shares of MAXIMUS by 7.5% in the second quarter. Strs Ohio now owns 10,000 shares of the health services provider’s stock valued at $725,000 after purchasing an additional 700 shares in the last quarter. Stratos Wealth Partners LTD. acquired a new position in shares of MAXIMUS in the first quarter valued at approximately $292,000. Geode Capital Management LLC grew its holdings in shares of MAXIMUS by 11.9% in the fourth quarter. Geode Capital Management LLC now owns 976,831 shares of the health services provider’s stock valued at $63,581,000 after purchasing an additional 103,638 shares in the last quarter. WINTON GROUP Ltd acquired a new position in shares of MAXIMUS in the second quarter valued at approximately $1,008,000. Finally, Mason Street Advisors LLC lifted its stake in MAXIMUS by 1.0% in the first quarter. Mason Street Advisors LLC now owns 33,926 shares of the health services provider’s stock worth $2,408,000 after acquiring an additional 333 shares during the last quarter. Hedge funds and other institutional investors own 94.79% of the company’s stock.

MAXIMUS stock traded down $1.89 during midday trading on Wednesday, hitting $79.52. 16,782 shares of the stock were exchanged, compared to its average volume of 281,837. MAXIMUS has a fifty-two week low of $60.00 and a fifty-two week high of $82.02. The stock has a market capitalization of $5.19 billion, a price-to-earnings ratio of 23.38, a PEG ratio of 2.16 and a beta of 0.88. The stock’s 50-day simple moving average is $76.06 and its 200 day simple moving average is $73.26.

The business also recently declared a quarterly dividend, which was paid on Friday, August 30th. Shareholders of record on Thursday, August 15th were given a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a dividend yield of 1.26%. The ex-dividend date of this dividend was Wednesday, August 14th. MAXIMUS’s dividend payout ratio is presently 29.41%.

MAXIMUS Company Profile

MAXIMUS, Inc provides business process services (BPS) to government health and human services programs worldwide. The company's Health Services segment offers various BPS, appeals, and assessments for state, provincial, and national government programs, including Medicaid, Children's Health Insurance Program, Affordable Care Act, Health Insurance British Columbia, Health Assessment Advisory Service contract, and Preadmission Screening and Resident Reviews.

Read More: Understanding Specialty Certificates of Deposit

Get a free copy of the Zacks research report on MAXIMUS (MMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for MAXIMUS (NYSE:MMS)

Receive News & Ratings for MAXIMUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MAXIMUS and related companies with MarketBeat.com's FREE daily email newsletter.